REACHing Communities (REACH) Consortium (U01) Clinical Trials Optional
Last verified by NonDilute: 2026-04-29. Official notice and agency instructions control.
If you lead a research institution with established community partnerships and multi-site trial infrastructure, REACH funding can scale your capacity to conduct inclusive, pragmatic clinical research.
Report stale or inaccurate summary
What this is
REACH is a consortium-based funding mechanism (U01 cooperative agreement) that supports large-scale, community-engaged clinical research networks. It emphasizes reaching underrepresented and underserved populations in clinical trials and building sustainable research infrastructure. Applicants should be well-established research institutions or consortia with existing infrastructure, community partnerships, and capacity to coordinate multi-site trials. Clinical trials component is optional, making this suitable for research organizations focused on health disparities, implementation science, or pragmatic trial design.
Who can apply
Eligible applicants are likely established research institutions, academic medical centers, and formal research consortia with demonstrated capacity for multi-site clinical research coordination and community engagement. Solo founders and early-stage startups are unlikely to be competitive; this is designed for organizations with existing research infrastructure and institutional review board (IRB) experience.
Topics: clinical trials · reach consortium · community engagement · health disparities · pragmatic trials · research networks · fda collaboration · multi-site research
Public-source funding discovery only. This summary is generated from public agency data and may be incomplete or stale. NonDilute is not affiliated with, endorsed by, or acting on behalf of any government agency. Official notices and agency instructions control. NonDilute does not determine eligibility, provide grant-writing advice, or guarantee funding.